Cerlapirdine
Overview[edit | edit source]
Cerlapirdine is a pharmaceutical drug that was investigated for its potential use in the treatment of cognitive disorders, particularly those associated with Alzheimer's disease. It is classified as a selective serotonin receptor antagonist, specifically targeting the 5-HT6 receptor.
Mechanism of Action[edit | edit source]
Cerlapirdine functions by selectively inhibiting the 5-HT6 receptor, a subtype of the serotonin receptor that is predominantly found in the central nervous system. The blockade of this receptor is believed to enhance the release of acetylcholine and other neurotransmitters, which are crucial for cognitive function. This mechanism suggests potential benefits in improving memory and learning in patients with cognitive impairments.
Development and Research[edit | edit source]
Cerlapirdine was developed as part of a broader effort to find effective treatments for neurodegenerative diseases. Initial studies focused on its ability to improve cognitive deficits in preclinical models. However, despite promising early results, further clinical trials were necessary to establish its efficacy and safety in humans.
Clinical Trials[edit | edit source]
Clinical trials for cerlapirdine aimed to assess its impact on cognitive function in patients with Alzheimer's disease. These trials were designed to evaluate both the safety profile and the therapeutic potential of the drug. Unfortunately, the outcomes of these trials did not demonstrate significant improvements over existing treatments, leading to a halt in its development.
Chemical Structure[edit | edit source]
Cerlapirdine is characterized by its unique chemical structure, which allows it to selectively bind to the 5-HT6 receptor. The molecular design was optimized to enhance its specificity and minimize off-target effects.
Potential Applications[edit | edit source]
While cerlapirdine did not advance to become a marketed drug, the research surrounding its development contributed valuable insights into the role of 5-HT6 receptors in cognitive processes. This knowledge continues to inform ongoing research in the field of neuropharmacology.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
